Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective stu...
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Mirogabalin, which is approved for the treatment of peripheral neuropathic pain in Japan, is a ligand for the α2δ subunit of voltage-gated calcium channels. Both pregabalin and mirogabalin act as nonselective ligands at the α2δ-1 and α2δ-2 subunits. Mirogabalin has a unique binding profile and long duration of action. Pregabalin has been reported t...
Alternative Titles
Full title
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c72ed1382f974ffc800257c0952ddc9f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c72ed1382f974ffc800257c0952ddc9f
Other Identifiers
ISSN
1749-799X
E-ISSN
1749-799X
DOI
10.1186/s13018-020-01709-3
